Skip to main navigation

  • Home

  • Development Programs

  • VX15 Immuno-Oncology

  • VX15 Neurology

  • VX18 Neurology

  • VX15 Autoimmune

  • NKT Vaccine

  • NKT Vaccine

  • ActivMAb®

  • Vaccinia Display

  • Capabilities

  • Optimization

  • Target Identification

  • Publications

  • News & Publications

    • News

    • Publications

  • Careers

  • Corporate

    • Management

    • Partners

    • Contact

  • Investors

    Main navigation

    • Investor Overview
    • News Releases
    • Events
    • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Corporate Governance
      • Documents & Charters
      • Management
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Investor Services
      • Information Request
      • IR Contacts
      • E-mail Alerts

  • Events

  • Presentations

  • Home

  • About

  • Corporate Overview

  • Management

  • Partners

  • Pipeline

  • Pepinemab
    Neurology

  • Pepinemab
    Immuno-Oncology

  • Research & Development Programs

  • Clinical Trials

  • Patients

  • Physicians & Researchers

  • News & Publications

    • News

    • Publications

  • Investors

    Main navigation

    • Investor Overview
    • News Releases
    • Events
    • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Corporate Governance
      • Documents & Charters
      • Management
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Investor Services
      • Information Request
      • IR Contacts
      • E-mail Alerts

  • Events

  • Presentations

  • Careers

  • Contact Us

  • ActivMAb ®

    • Vaccinia

    • Antibody Discovery

    • Antigen Virus

    • Protein Optimization

    • Antigen Discovery

    • Antibody Optimization

    • ActivMAb ® Contact

Science in the service of medicine
  • About
    • Corporate Overview
    • Management
    • Partners
  • Pipeline
    • Pepinemab Neurology
    • Pepinemab Immuno-Oncology
    • Research & Development Programs
  • Clinical Trials
    • Patients
    • Physicians & Researchers
  • News & Publications
    • News
    • Publications
  • Investors

    Main navigation

    • Investor Overview
    • News Releases
    • Events
    • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Corporate Governance
      • Documents & Charters
      • Management
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Investor Services
      • Information Request
      • IR Contacts
      • E-mail Alerts
  • Events
  • Presentations
  • Careers
  • Contact Us
  • ActivMAb ®
    • Vaccinia
    • Antibody Discovery
    • Antigen Virus
    • Protein Optimization
    • Antigen Discovery
    • Antibody Optimization
    • Contact Us

News Releases

News Releases

Investors

  • Investor Overview
  • News Releases
  • Events
  • Presentations
  • Stock Information
  • Corporate Governance
  • Financial Information
  • Investor Services

Shareholder Tools

  • Print Page
  • RSS Feeds
  • E-mail Alerts
  • IR Contacts
  • LinkedIn
  • Twitter

News Releases

Keyword Search

01/26/22
Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer
01/04/22
Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis

  • About
  • Pipeline
  • Clinical Trials
  • News
  • Careers
  • Contact
Vaccinex Inc.
1895 Mount Hope Avenue, Rochester, NY 14620
P: 585-271-2700
F: 585-271-2765
info@vaccinex.com
  • © 2022 Vaccinex. All rights reserved
    • |
  • Privacy Policy
    • |
  • Site by Minerva